top of page

Otricath
Potential Advantages

Patients: Enables a More Targeted Treatment Approach

Otricath™ is being developed to create a temporary treatment environment that enables localized delivery and recovery of therapeutic agents. Potential benefits may include:​

  • Increase local concentration of therapeutic agents

  • Reduced systemic washout of toxic therapeutic agents

  • Minimally invasive catheter-based procedure

  • Potential to support more focused treatment strategies

  • Designed to integrate into existing interventional oncology treatment pathways

Clinicians: Greater Control Over Therapy Delivery

Otricath™ is designed to provide physicians with enhanced control over therapy administration within the target treatment region. Potential benefits may include: 

  • Better targeting of treatment region with temporary creation of an isolated treatment environment

  • Better drug delivery and recovery within a single catheter platfor with effective control of regional perfusion dynamics

  • Faster learning curve noting Otricath workflow compatibility with existing catheter-based procedures. 

Hospitals & Healthcare Systems: Otricath is designed around procedural efficiency. 

 Potential benefits may include: 

  • Less Minimally invasive approach

  • Cost Savings leveraging a 3 in 1 catheter platform for targeting, drug delivery and aspiration. 

  • Increased efficiency with a streamlined  single catheter workflow compared with more complex perfusion systems

  • Potential expansion of regional therapy capabilities within existing service lines

Strategic & Industry Partners

​Otricath™ is being developed as a therapeutic delivery platform with potential applications across multiple treatment modalities, disease states, and future drug-device combinations. The platform is designed to support localized delivery and therapeutic recovery within a single procedural workflow, creating opportunities for future clinical, commercial, and strategic collaboration. For pharmaceutical companies, biotechnology innovators, and strategic partners, Otricath™ may represent a future platform for exploring localized therapeutic delivery approaches across a broad range of oncology applications and treatment modalities.  Potential areas of exploration include:

​

  • Regional oncology therapies

  • Liver tumors and liver metastases

  • Additional solid tumor applications

  • Chemotherapy and biologic therapies

  • Immunotherapy and antibody-drug conjugates (ADCs)

  • Cell and gene therapies

  • Emerging targeted therapeutic strategies

​​

​

​

​

​

​

Important Regulatory Notice

Otricath™ is an investigational device currently under development. Otricath™ has not been cleared or approved by the U.S. Food and Drug Administration (FDA) and is not available for commercial sale. Statements on this website describe the technology under development and are not intended to represent claims of safety or effectiveness.

​

bottom of page